You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德展健康(000813.SZ):2019年淨利達3.37億元 經營性現金流大幅提升
格隆匯 04-28 17:05

格隆匯4月28日丨德展健康(000813.SZ)披露2019年年度報告,報告期內,公司實現營業收入17.75億元,同比下降46.06%;歸屬於上市公司股東的淨利潤3.37億元,同比下降63.79%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.55億元,同比下降72.38%;經營活動現金淨流入15.59億元,同比增長310.45%;基本每股收益0.1519元。

2019年3月起“4+7”帶量採購開始正式逐步實施,隨着帶量採購的推進實施,報告期內,主打產品“阿樂”在11個帶量採購試點城市銷售量大幅提升,帶量採購工作順利開展,全年無斷貨情況發生,且貨款都安全回收。同時,為保證銷售市場公平有序發展,協助代理商良好的管控貨物銷售渠道,雖然“帶量地區”與“非帶量地區”存在較大的差價,但並未因此造成市場混亂。

但是,由於在藥品大幅降價背景下,“非帶量”地區經銷商對於市場信心不足,擔心本地區隨時跟進帶量採購,備貨庫存量大大降低,在一定程度上帶來了銷售量的降低,致使非帶量地區阿樂銷量未完成預期。在9月份帶量採購全面擴圍後,公司及時調整營銷戰略,加大對零售端市場推廣力度,逐步將營銷重心轉移到零售端市場。報告期內公司主打產品“阿樂”全年實現銷量2.35億盒(按10mg計算)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account